Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
177.35 ^USD	+0.76%		+2.53%	+0.77%

Apr. 16	US FDA's accelerated approval for drugs needs more transparency, says research firm	RE
Apr. 15	GSK plc Receives Additional Marketing Approval for Depemokimab	CI

Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026

Published on 03/11/2026 at 05:28 pm EDT

S&P Capital IQ

BIOGEN INC.

+0.76%

Biogen Inc. announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end of May, 2026. The Company has initiated a search to identify the Company's next Chief Legal Officer.

Latest news about Biogen Inc.

Apr. 16	US FDA's accelerated approval for drugs needs more transparency, says research firm	RE
Apr. 15	GSK plc Receives Additional Marketing Approval for Depemokimab	CI
Apr. 14	Biogen Shares Rise After Piper Sandler Upgrade	MT
Apr. 14	Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast…
Apr. 14	Piper Sandler Upgrades Biogen to Overweight From Neutral, Adjusts Price Target to $214 From $177	MT
Apr. 13	Citigroup Adjusts Price Target on Biogen to $190 From $215, Maintains Neutral Rating	MT
Apr. 07	Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update	DJ
Apr. 07	RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating	MT
Apr. 07	Biogen Enters Collaboration, License Agreement With Alloy Therapeutics	MT
Apr. 07	Alloy Therapeutics enters into multi-target collaboration and license agreement with Biogen for use of Alloy's Anticlastic™ ASO platform	RE
Apr. 07	Alloy Therapeutics Inc. And Biogen Inc. Enter Into Multi-Target Collaboration And License Agreement For Use Of Alloy?s Anticlastic ASO Platform	CI
Apr. 06	Top Midday Stories: Iran Reportedly Rejects Proposed Ceasefire; Soleno Shares Rise After $2.9 Billion Neurocrine Deal	MT
Apr. 06	Biogen Expects to Take $0.19 per Share Charge in Q1	MT
Apr. 06	Biogen - Expects Q1 2026 GAAP and non-GAAP EPS impact of $0.19 from charge - SEC filing	RE
Apr. 02	From Hope to Nope

Chart Biogen Inc.

Duration

Period

BIIB: Dynamic Chart

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.

Employees

7,500

Sector

Pharmaceuticals

Calendar

Apr. 29 - Earnings release - Q1 2026

More about the company